EMA's CHMP recommends J&J's Tremfya for plaque psoriasis
EMA’s CHMP recommended approval of Tremfya guselkumab (CNTO 1959) from Johnson & Johnson (NYSE:JNJ) to treat moderate to severe plaque psoriasis in patients who are candidates for systemic therapy. The human HuCAL mAb targeting the p19 subunit of IL-23 was approved by FDA in July (see BioCentury, July 14)...
BCIQ Target Profiles